Other Events ·
Cardiff Oncology and Nerviano Medical Sciences entered a Confidential Settlement Agreement to resolve patent…
CRDFCardiff Oncology, Inc.
Cardiff Oncology and Nerviano Medical Sciences entered a Confidential Settlement Agreement to resolve patent inventorship and license performance litigation, dismissing the case with prejudice without monetary payment. Concurrently, they executed an Amendment to their 2017 Exclusive License Agreement for onvansertib, establishing an updated exclusivity framework preventing Nerviano from developing competing products. The amendment introduces additional license fees based on annual net sales of Company-patented products, revised post-termination royalty tiers, and development milestones tied to the upcoming Phase 3 program in first-line RAS-mutated metastatic colorectal cancer. Nerviano gains a board observer seat and a Scientific Advisory Board position, while termination-for-cause provisions now require judicial or arbitral determination of material breach. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition.